Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Nanobiotechnology ; 18(1): 89, 2020 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-32527262

RESUMEN

BACKGROUND: Farnesol is a sesquiterpene from propolis and citrus fruit that shows promising anti-bacterial activity for caries treatment and prevention, but its hydrophobicity limits the clinical application. We aimed to develop the novel polymeric micelles (PMs) containing a kind of derivative of farnesol and a ligand of pyrophosphate (PPi) that mediated PMs to adhere tightly with the tooth enamel. RESULTS: Farnesal (Far) was derived from farnesol and successfully linked to PEG via an acid-labile hydrazone bond to form PEG-hyd-Far, which was then conjugated to PPi and loaded into PMs to form the aimed novel drug delivery system, PPi-Far-PMs. The in vitro test about the binding of PPi-Far-PMs to hydroxyapatite showed that PPi-Far-PMs could bind rapidly to hydroxyapatite and quickly release Far under the acidic conditions. Results from the mechanical testing and the micro-computed tomography indicated that PPi-Far-PMs could restore the microarchitecture of teeth with caries. Moreover, PPi-Far-PMs diminished the incidence and severity of smooth and sulcal surface caries in rats that were infected with Streptococcus mutans while being fed with a high-sucrose diet. The anti-caries efficacy of free Far can be improved significantly by PPi-Far-PMs through the effective binding of it with tooth enamel via PPi. CONCLUSIONS: This novel drug-delivery system may be useful for the treatment and prevention of dental caries as well as the targeting therapy of anti-bacterial drugs in the oral disease.


Asunto(s)
Cariostáticos , Caries Dental , Durapatita , Farnesol/análogos & derivados , Micelas , Animales , Cariostáticos/química , Cariostáticos/farmacocinética , Cariostáticos/farmacología , Caries Dental/tratamiento farmacológico , Caries Dental/metabolismo , Caries Dental/patología , Difosfatos/química , Difosfatos/farmacocinética , Difosfatos/farmacología , Portadores de Fármacos , Durapatita/química , Durapatita/metabolismo , Farnesol/química , Farnesol/farmacocinética , Farnesol/farmacología , Interacciones Hidrofóbicas e Hidrofílicas , Diente Molar/efectos de los fármacos , Diente Molar/ultraestructura , Polietilenglicoles/química , Ratas , Streptococcus mutans/efectos de los fármacos
2.
Molecules ; 23(11)2018 Nov 21.
Artículo en Inglés | MEDLINE | ID: mdl-30469331

RESUMEN

Hop-derived compounds have been subjected to numerous biomedical studies investigating their impact on a wide range of pathologies. Isomerised bitter acids (isoadhumulone, isocohumulone and isohumulone) from hops, used in the brewing process of beer, are known to inhibit members of the aldo-keto-reductase superfamily. Aldo-keto-reductase 1B10 (AKR1B10) is upregulated in various types of cancer and has been reported to promote carcinogenesis. Inhibition of AKR1B10 appears to be an attractive means to specifically treat RAS-dependent malignancies. However, the closely related reductases AKR1A1 and AKR1B1, which fulfil important roles in the detoxification of endogenous and xenobiotic carbonyl compounds oftentimes crossreact with inhibitors designed to target AKR1B10. Accordingly, there is an ongoing search for selective AKR1B10 inhibitors that do not interact with endogeneous AKR1A1 and AKR1B1-driven detoxification systems. In this study, unisomerised α-acids (adhumulone, cohumulone and n-humulone) were separated and tested for their inhibitory potential on AKR1A1, AKR1B1 and AKR1B10. Also AKR1B10-mediated farnesal reduction was effectively inhibited by α-acid congeners with Ki-values ranging from 16.79 ± 1.33 µM (adhumulone) to 3.94 ± 0.33 µM (n-humulone). Overall, α-acids showed a strong inhibition with selectivity (115⁻137 fold) for AKR1B10. The results presented herein characterise hop-derived α-acids as a promising basis for the development of novel and selective AKR1B10-inhibitors.


Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Ciclohexanonas/farmacología , Ciclohexenos/farmacología , Terpenos/farmacología , Aldehído Reductasa/metabolismo , Aldo-Ceto Reductasas , Evaluación Preclínica de Medicamentos , Ensayos de Selección de Medicamentos Antitumorales , Farnesol/análogos & derivados , Farnesol/química , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Humanos , Humulus/química
3.
Food Chem ; 263: 155-162, 2018 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-29784301

RESUMEN

Ganoderma fungi have long been used as a famous traditional medicine and food in country of East Asia. In this work, two new farnesyl phenolic compounds, ganoduriporols A and B (1 and 2), were isolated from the fruiting bodies of Ganoderma duripora, and their structures were elucidated using various spectroscopic methods. Anti-inflammatory activities were assayed and evaluated for the two compounds. Ganoduriporols A and B exhibited dose-dependent anti-inflammatory effects in RAW 264.7 cells. Furthermore, ganoduriporol A was demonstrated to inhibit the production of tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), interleukin-6 (IL-6) and prostaglandin E2 (PGE2) through the suppression of COX-2, MAPK and NF-κB signaling pathway in LPS-induced macrophage cells. These results suggested that these two new farnesyl phenolic compounds and the fruiting body of G. duripora could serve as anti-inflammatory agents for medicinal use or functional food.


Asunto(s)
Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Farnesol/análogos & derivados , Farnesol/farmacología , Ganoderma/química , Fenoles/farmacología , Animales , Ciclooxigenasa 2/metabolismo , Dinoprostona/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Lipopolisacáridos/farmacología , Ratones , Estructura Molecular , FN-kappa B/metabolismo , Óxido Nítrico/metabolismo , Células RAW 264.7 , Transducción de Señal/efectos de los fármacos , Factor de Necrosis Tumoral alfa/metabolismo
4.
ChemMedChem ; 10(6): 971-6, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25882299

RESUMEN

A novel series of hybrids was designed and synthesized by combining key elements from farnesylthiosalicylic acid (FTS) and hydroxamic acid. Several 3,7,11-trimethyldodeca-2,6,10-trien-1-yl) thio)benzamide derivatives, particularly those with branched and linear aliphatic linkers between the hydroxamic zinc binding group (ZBG) and the benzamide core, not only displayed significant antitumor activities against six human cancer cells but also exhibited histone deacetylase (HDAC) inhibitory effects in vitro. Among them, N-(4-(hydroxyamino)-4-oxobutyl)-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6, 10-trien-1-yl)thio)benzamide (8 d) was the most potent, with IC50 values of 4.9-7.6 µM; these activities are eight- to sixteen-fold more potent than FTS and comparable to that of suberoylanilide hydroxamic acid (SAHA). Derivative 8 d induced cell cycle arrest in the G0/G1 phase, inhibited the acetylation of histone H3 and α-tubulin, and blocked Ras-related signaling pathways in a dose-dependent manner. The improved tumor growth inhibition and cell-cycle arrest in vitro might result from the dual inhibition. These findings suggest dual inhibitors of Ras-related signaling pathway and HDAC hold promise as therapeutic agents for the treatment of cancer.


Asunto(s)
Farnesol/análogos & derivados , Inhibidores de Histona Desacetilasas/farmacología , Ácidos Hidroxámicos/farmacología , Salicilatos/farmacología , Línea Celular , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Farnesol/química , Farnesol/farmacología , Inhibidores de Histona Desacetilasas/química , Humanos , Ácidos Hidroxámicos/química , Salicilatos/química
5.
AAPS J ; 16(3): 600-8, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24706375

RESUMEN

Curcumin and S-trans, trans-farnesylthiosalicylic acid (FTS) are two promising anticancer agents. In this study, we demonstrated that the two agents exerted significant synergy in antitumor activity in various types of cancer cells with combination indices ranging from 0.46 to 0.98 (a value of less than unity indicates synergism). We have further shown that synergistic-targeted co-delivery of the two agents can be achieved via formulating curcumin in polyethylene glycol (PEG)-derivatized FTS-based nanomicellar system. Curcumin formulated in PEG-FTS micelles had small size of around 20 nm. The nanomicellar curcumin demonstrated enhanced cytotoxicity towards several cancer cell lines in vitro. Intravenous application of curcumin-loaded micelle (20 mg kg(-1) curcumin) led to a significantly more effective inhibition of tumor growth in a syngeneic mouse breast cancer model (4T1.2) than curcumin formulated in Cremophor/EL (P < 0.05).


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos Fitogénicos/administración & dosificación , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Curcumina/administración & dosificación , Sistemas de Liberación de Medicamentos , Farnesol/administración & dosificación , Farnesol/análogos & derivados , Femenino , Ratones , Ratones Endogámicos BALB C , Micelas , FN-kappa B/efectos de los fármacos , Polietilenglicoles , Proteínas Proto-Oncogénicas c-akt/efectos de los fármacos , Salicilatos/administración & dosificación , Transducción de Señal/efectos de los fármacos
6.
Fitoterapia ; 93: 189-93, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24444894

RESUMEN

3-Farnesyl-2-hydroxybenzoic acid is an antibacterial agent isolated from the leaves of Piper multiplinervium. This compound has activity against both Gram positive and Gram negative bacteria including Escherichia coli, Staphylococcus aureus and Helicobacter pylori. This research aimed to synthesize a natural antibacterial compound and its analogs. The synthesis of 3-Farnesyl-2-hydroxybenzoic acid consists of three steps: straightforward synthesis involving protection of phenolic hydroxyl group, coupling of suitable isoprenyl chain to the protected aromatic ring at ortho position followed by carboxylation with concomitant deprotection to give the derivatives of the salicylic acid. All the three prenylated compounds synthesized were found to exhibit spectrum of activity against S. aureus (ATCC) having MIC: 5.84×10(-3), 41.46×10(-2) and 6.19×10(-1) µmol/ml respectively. The compounds also displayed activity against resistance strain of S. aureus (SA1119B) having MIC: 5.84×10(-3), 7.29×10(-3) and 3.09×10(-1) µmol/ml respectively. This synthesis has been achieved and accomplished with the confirmation of it structure to that of the original natural product, thus producing the first synthesis of the natural product and providing the first synthesis of its analogs with 3-Farnesyl-2-hydroxybenzoic acid having biological activity higher than that of the original natural product.


Asunto(s)
Antibacterianos/síntesis química , Farnesol/análogos & derivados , Hidroxibenzoatos/síntesis química , Piper/química , Farnesol/síntesis química , Pruebas de Sensibilidad Microbiana , Plantas Medicinales/química
7.
J Ethnopharmacol ; 103(3): 461-7, 2006 Feb 20.
Artículo en Inglés | MEDLINE | ID: mdl-16266794

RESUMEN

A new prenylated salicylic acid derivative, 3-farnesyl-2-hydroxy benzoic acid (1), was isolated from the leaves of Piper multiplinervium C. DC. (Piperaceae). It showed anti-Helicobacter pylori activity (MIC 37.5 microg/ml) and antimicrobial activity at MICs between 2.5 and 5 microg/ml against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Mycobacterium smegmatis, Pseudomonas aeruginosa and Candida albicans. Its structure was elucidated by means of MS, 1H and 13C NMR. The ethnomedical claim of Piper multiplinervium to treat stomach aches by the Kuna Indians of Panama may be justified by anti-Helicobacter pylori activity of its MeOH extract.


Asunto(s)
Antiinfecciosos/farmacología , Farnesol/análogos & derivados , Helicobacter pylori/efectos de los fármacos , Hidroxibenzoatos/farmacología , Piper/química , Antiinfecciosos/aislamiento & purificación , Escherichia coli/efectos de los fármacos , Escherichia coli/crecimiento & desarrollo , Farnesol/farmacología , Helicobacter pylori/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Panamá , Hojas de la Planta , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/crecimiento & desarrollo
8.
J Lipid Res ; 44(1): 128-35, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12518031

RESUMEN

We recently demonstrated that squalene synthase (SQS) inhibitors reduce plasma triglyceride through an LDL receptor-independent mechanism in Watanabe heritable hyperlipidemic rabbits (Hiyoshi et al. 2001. Eur. J. Pharmacol. 431: 345-352). The present study deals with the mechanism of the inhibition of triglyceride biosynthesis by the SQS inhibitors ER-27856 and RPR-107393 in rat primary cultured hepatocytes. Atorvastatin, an HMG-CoA reductase inhibitor, had no effect on triglyceride biosynthesis, but reversed the inhibitory effect of the SQS inhibitors. A squalene epoxidase inhibitor, NB-598, affected neither triglyceride biosynthesis nor its inhibition by ER-27856 and RPR-107393. The reduction of triglyceride biosynthesis by ER-27856 and RPR-107393 was potentiated by mevalonolactone supplementation. Treatment of hepatocytes with farnesol and its derivatives reduced triglyceride biosynthesis. In addition, we found that ER-27856 and RPR-107393 significantly reduced the incorporation of [1-(14)C]acetic acid into oleic acid, but not the incorporation of [1-(14)C]oleic acid into triglyceride. Though ER-27856 and RPR-107393 increased mitochondrial fatty acid beta-oxidation, the inhibition of beta-oxidation by RS-etomoxir had little effect on their inhibition of triglyceride biosynthesis. These results suggest that SQS inhibitors reduce triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives.


Asunto(s)
Inhibidores Enzimáticos/farmacología , Farnesol/metabolismo , Farnesil Difosfato Farnesil Transferasa/antagonistas & inhibidores , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Triglicéridos/biosíntesis , Animales , Atorvastatina , Bencilaminas/farmacología , Células Cultivadas , Colesterol/biosíntesis , Farnesol/análogos & derivados , Farnesol/farmacología , Ácidos Heptanoicos/farmacología , Metabolismo de los Lípidos , Masculino , Oxidación-Reducción , Pirroles/farmacología , Ratas , Ratas Sprague-Dawley , Tiofenos/farmacología
9.
FEBS Lett ; 514(2-3): 250-4, 2002 Mar 13.
Artículo en Inglés | MEDLINE | ID: mdl-11943160

RESUMEN

1-Farnesylpyridinium (FPy), an analog of isoprenoid farnesol, initially induced morphological changes similar to those of typical apoptosis in human leukemia HL-60 cells but FPy-treated cells were characterized by the absolute absence of final apoptotic events such as fragmentation into apoptotic bodies. FPy-induced cell death was considered to be apoptotic on the basis of the induction of DNA fragmentation and the protection against these events by the coaddition of a pan-caspase inhibitor. The increase in the cytoplasmic cytochrome c level supported the possibility that FPy-treated cells should have the ability to complete the entire apoptotic process ending in cell fragmentation and apoptotic body formation. At concentrations too low to induce apoptosis, FPy could suppress the induction of apoptotic body formation in HL-60 cells by typical inducers of apoptosis such as actinomycin D or anisomycin. FPy exhibited a cytochalasin-like effect on spatial arrangement of actin filament independent of its apoptosis-inducing activity.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis , Citocalasina B/análogos & derivados , Farnesol/análogos & derivados , Cuerpos de Inclusión/efectos de los fármacos , Leucemia Promielocítica Aguda/tratamiento farmacológico , Compuestos de Piridinio/farmacología , Sesquiterpenos/farmacología , Citoesqueleto de Actina/efectos de los fármacos , Citoesqueleto de Actina/metabolismo , Antineoplásicos/síntesis química , Apoptosis/efectos de los fármacos , Inhibidores de Caspasas , Inhibidores de Cisteína Proteinasa/farmacología , Citocalasina B/farmacología , ADN/metabolismo , Fragmentación del ADN/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Farnesol/química , Farnesol/farmacología , Células HL-60 , Humanos , Cuerpos de Inclusión/patología , Leucemia Promielocítica Aguda/metabolismo , Leucemia Promielocítica Aguda/patología , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiología , Inhibidores de la Síntesis del Ácido Nucleico/farmacología , Inhibidores de la Síntesis de la Proteína/farmacología , Compuestos de Piridinio/síntesis química , Sesquiterpenos/síntesis química
10.
Cell ; 81(5): 687-93, 1995 Jun 02.
Artículo en Inglés | MEDLINE | ID: mdl-7774010

RESUMEN

Nuclear hormone receptors comprise a superfamily of ligand-modulated transcription factors that mediate the transcriptional activities of steroids, retinoids, and thyroid hormones. A growing number of related proteins have been identified that possess the structural features of hormone receptors, but that lack known ligands. Known as orphan receptors, these proteins represent targets for novel signaling molecules. We have isolated a mammalian orphan receptor that forms a heterodimeric complex with the retinoid X receptor. A screen of candidate ligands identified farnesol and related metabolites as effective activators of this complex. Farnesol metabolites are generated intracellularly and are required for the synthesis of cholesterol, bile acids, steroids, retinoids, and farnesylated proteins. Intermediary metabolites have been recognized as transcriptional regulators in bacteria and yeast. Our results now suggest that metabolite-controlled intracellular signaling systems are utilized by higher organisms.


Asunto(s)
Proteínas de Unión al ADN/metabolismo , Farnesol/metabolismo , Transducción de Señal , Factores de Transcripción/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Northern Blotting , Células Cultivadas , ADN/metabolismo , ADN Complementario/genética , Proteínas de Unión al ADN/genética , Farnesol/análogos & derivados , Humanos , Ratones , Datos de Secuencia Molecular , Ratas , Receptores Citoplasmáticos y Nucleares , Receptores de Ácido Retinoico/metabolismo , Receptores X Retinoide , Terpenos/metabolismo , Factores de Transcripción/genética , Transcripción Genética , Transfección
11.
Gen Comp Endocrinol ; 80(2): 232-7, 1990 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-2074002

RESUMEN

Methyl farnesoate (MF) is secreted by the mandibular organs of crustaceans, but its physiological role and biochemical distribution are only partially known. Characterization of specific MF binding proteins (MFBP) in homogenates of tissues of the American lobster, Homarus americanus, was achieved by photoaffinity labeling with tritium-labeled farnesyl diazomethyl ketone (3H-FDK). The tissues selected include epidermis, tail muscle, central nervous system, eyestalk, hemolymph, hepatopancreas, ovaries, testes, and Y-organ. Both high-speed pellets and supernatants were tested. Competing ligands employed to verify specificity of light-induced covalent modification included MF, methoprene, and unlabeled FDK. A 40-kDa band was labeled strongly in the hemolymph; the labeling was displaced in the presence of a 100-fold excess of unlabeled MF. Although many other tissues had proteins which labeled with 3H-FDK, none of these showed competition by MF. This MFBP is thus functionally analogous to the hemolymph JH-binding proteins of insects.


Asunto(s)
Marcadores de Afinidad , Proteínas Portadoras/análisis , Ácidos Grasos Insaturados/metabolismo , Nephropidae/metabolismo , Animales , Unión Competitiva , Proteínas Portadoras/metabolismo , Diazometano/análogos & derivados , Diazometano/metabolismo , Farnesol/análogos & derivados , Farnesol/metabolismo , Femenino , Hemolinfa/química , Fotoquímica , Distribución Tisular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA